144870-96-2 Usage
General Description
3-Furanol,4-aminotetrahydro-(9CI) is a chemical compound classified under furanes that is not widely documented. As its name indicates, it is a derivative of furanol, a heterocyclic organic compound, consisting of a five-membered aromatic ring with four carbon atoms and one oxygen atom. The "aminotetrahydro" portion of its name suggests that the compound also has an amino group (-NH2) and a tetrahydro structural piece (four hydrogen atoms) in its configuration. However, due to the lack of substantial data available, detailed characteristics including its uses, toxicity, physical properties, and health impacts are currently not well-known or thoroughly documented.
Check Digit Verification of cas no
The CAS Registry Mumber 144870-96-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,4,4,8,7 and 0 respectively; the second part has 2 digits, 9 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 144870-96:
(8*1)+(7*4)+(6*4)+(5*8)+(4*7)+(3*0)+(2*9)+(1*6)=152
152 % 10 = 2
So 144870-96-2 is a valid CAS Registry Number.
144870-96-2Relevant articles and documents
Bronsted acid-catalyzed desymmetrization of meso-aziridines
Rowland, Emily B.,Rowland, Gerald B.,Rivera-Otero, Edwin,Antilla, Jon C.
, p. 12084 - 12085 (2007)
The enantioselective ring-opening of meso-aziridines with azide nucleophiles proceeded in the presence of a catalytic amount of a chiral phosphoric acid catalyst. The reaction affords the formation of the products in excellent yield and enantioselectivity. Preliminary mechanistic studies indicate that the active catalytic species is a chiral silane that is generated in situ. Copyright
HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS
-
Paragraph 0489, (2021/01/23)
Heterocyclic compounds as CDK4 or CDK6 or other CDK inhibitors are provided. The compounds may find use as therapeutic agents for the treatment of diseases and may find particular use in oncology.
SELECTIVE ANDROGEN RECEPTOR MODULATORS
-
Page/Page column 38-39, (2013/04/25)
The present invention provides novel selective androgen receptor modulators and their salts and pharmaceutical compositions thereof.
